Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue From Contracts With Customers (Tables)

v3.21.2
Note 3 - Revenue From Contracts With Customers (Tables)
6 Months Ended
Jun. 30, 2021
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
   

2021

   

2020

   

2021

   

2020

 

Royalty revenue:

                               

Tc99m tilmanocept - Europe

  $     $ 8,920     $     $ 24,141  
                                 

License revenue:

                               

Tc99m tilmanocept - Europe

  $ 13,063     $     $ 35,549     $  
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
   

2021

   

2020

   

2021

   

2020

 

Total deferred revenue, beginning of period

  $ 700,000     $ 700,000     $ 700,000     $ 700,000  

Revenue deferred related to sublicense

          160,000             160,000  

Revenue recognized from satisfaction of performance obligations

                       

Total deferred revenue, end of period

  $ 700,000     $ 860,000     $ 700,000     $ 860,000